Aristolochic acid-associated urothelial cancer in Taiwan

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 21, 2012, Pages 8241-8246

  Chen, Chung Hsin ^a,b   Dickman, Kathleen G ^c   Moriya, Masaaki ^c   Zavadil, Jiri ^d   Sidorenko, Viktoriya S ^c   Edwards, Karen L ^e   Gnatenko, Dmitri V ^c   Wu, Lin ^f   Turesky, Robert J ^g   Wu, Xue Ru ^h   Pu, Yeong Shiau ^a   Grollman, Arthur P ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAOYUAN GENERAL HOSPITAL   (Taiwan)

^c STONY BROOK UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f ROCHE MOLECULAR SYSTEMS   (United States)

^g WADSWORTH CENTER   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA damage; Herbal medicine; Traditional Chinese medicine; Transitional cell carcinoma; Upper urinary tract carcinoma

Indexed keywords

ARISTOLOCHIC ACID; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA ADDUCT; FEMALE; GENE MUTATION; HUMAN; IATROGENIC DISEASE; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; TAIWAN; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ARISTOLOCHIC ACIDS; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; DNA ADDUCTS; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTAGENS; ONCOGENES; TAIWAN; TUMOR SUPPRESSOR PROTEIN P53; URETERAL NEOPLASMS; UROTHELIUM;

ARISTOLOCHIA;

EID: 84861428636     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1119920109     Document Type: Article

References (40)

1. Grollman AP, Scarborough J, Jelaković B (2009) Aristolochic acid nephropathy: An environmental and iatrogenic disease. Advances in Molecular Toxicology, ed Fishbein JC (Elsevier, Amsterdam), 3rd Ed, pp 211-222.
2. Vanherweghem JL, Debelle F, Muniz-Martinez MC, Nortier JL (2003) Aristolochic acid nephropathy after Chinese herb remedies. Clinical Nephrotoxins, eds De Broe ME, Porter GA, Bennett WM, Verpooten GA (Kluwer, Dordrecht), 2nd Ed, pp 588-601.
3. Nortier JL, et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342:1686-1692. (Pubitemid 30354515)
4. National Toxicology Program (2011) Aristolochic acids. Rep Carcinog 12:45-49.
5. Debelle FD, Vanherweghem JL, Nortier JL (2008) Aristolochic acid nephropathy: A worldwide problem. Kidney Int 74:158-169. (Pubitemid 351915079)
6. Grollman AP, et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104:12129-12134. (Pubitemid 47185641)
7. Jelaković B, et al. (2012) Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 81:559-567.
8. Petronić V (2000) Tumors of the upper urothelium and endemic nephropathy. Endemic Nephropathy, eds Radovanović Z, Sindić M, Polenaković M, Djukanović L, Petronić V (Institute for Textbook Publishing, Belgrade, Serbia), pp 350-439.
9. Nikolić J (2006) Epidemic nephropathy and upper urothelial tumors, Izdavačko preduzeće (Beograd AD, Belgrade, Serbia).
10. Hranjec T, et al. (2005) Endemic nephropathy: The case for chronic poisoning by Aristolochia. Croat Med J 46:116-125. (Pubitemid 40469936)
11. Arlt VM, Stiborova M, Schmeiser HH (2002) Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis 17:265-277. (Pubitemid 34814645)
12. Moriya M, et al. (2011) TP53 Mutational signature for aristolochic acid: An environmental carcinogen. Int J Cancer 129:1532-1536.
13. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD (2010) Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102:179-186.
14. Hsieh SC, Lin IH, Tseng WL, Lee CH, Wang JD (2008) Prescription profile of potentially aristolochic acid containing Chinese herbal products: An analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin Med 3:13.
15. Lai MN, et al. (2010) Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: A population-based case-control study. Am J Kidney Dis 55:507-518.
16. Olivier M, et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 19:607-614. (Pubitemid 34556481)
17. Wu XR (2005) Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5:713-725.
18. Kompier LC, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5: e13821.
19. McLaughlin JK, et al. (1992) Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res 52:254-257.
20. Colin P, et al. (2009) Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 104:1436-1440.
21. Levey AS, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247-254. (Pubitemid 46768608)
22. Levey AS, et al. (2005) Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089-2100. (Pubitemid 41623371)
23. Nedelko T, Arlt VM, Phillips DH, Hollstein M (2009) TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 124:987-990.
24. Mitra AP, Birkhahn M, Cote RJ (2007) p53 and retinoblastoma pathways in bladder cancer. World J Urol 25:563-571.
25. Burkhart DL, Sage J (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8:671-682.
26. van Oers JM, et al. (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55:650-657.
27. Attaluri S, et al. (2010) DNA adducts of aristolochic acid II: Total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res 38:339-352.
28. Lukin M, Zaliznyak T, Johnson F, de Los Santos C (2012) Structure and stability of DNA containing an aristolactam II-dA lesion: Implications for the NER recognition of bulky adducts. Nucleic Acids Res 40:2759-2770.
29. Sidorenko VS, et al. (2012) Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res 40:2494-2505.
30. Chen CL, et al. (2010) Arsenic in drinking water and risk of urinary tract cancer: A follow-up study from northeastern Taiwan. Cancer Epidemiol Biomarkers Prev 19:101-110.
31. Wang JD (2006) Establishment of an active surveillance system for Chinese herbal medicine. Yearbook Chinese Medicine and Pharmacy 24:157-280.
32. Ferlay J, et al. (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (International Agency for Research on Cancer, Lyon, France). Available from: http://globocan.iarc.fr. Accessed October 18, 2010.
33. Bureau of Health Promotion, Deptartment of Health, Taiwan. The incidence of bladder, renal pelvic and ureteral tumor in Taiwan, https://cris.bhp.doh.gov. tw/pagepub/Home.aspx?itemNo=cr.q.10. Accessed March 15, 2011.
34. Chen CY, Liao YM, Tsai WM, Kuo HC (2007) Upper urinary tract urothelial carcinoma in eastern Taiwan: High proportion among all urothelial carcinomas and correlation with chronic kidney disease. J Formos Med Assoc 106:992-998.
35. Wu KM, Farrelly JG, Upton R, Chen J (2007) Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): Lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 14:273-279. (Pubitemid 46386394)
36. Zhu YP (2002) Toxicity of the Chinese herb mu tong (Aristolochia manshuriensis). What history tells us. Adverse Drug React Toxicol Rev 21:171-177.
37. China State Food and Drug Administration (2003) Suspension of Traditional Chinese Medicine Standard on Guan Mutong, April 1 announcement, Notice no. 121. Available at http://www.zhong-yao.net/shi/24631.htm. Accessed December 1, 2011.
38. Chuang MS, Hsu YH, Chang HC, Lin JH, Liao CH (2002) Studies on adulteration and misuage of marketed Akebiae caulis. Ann Rept NLFD Taiwan ROC 20:104-119.
39. Martena MJ, et al. (2007) Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal Bioanal Chem 389:263-275. (Pubitemid 47325230)
40. Segi M, Fujisaku S, Kurihara M, Narai Y, Sasajima K (1960) The age-adjusted death rates for malignant neoplasms in some selected sites in 23 countries in 1954-1955 and their geographical correlation. Tohoku J Exp Med 72:91-103.